To investigate this, we applied a combined (targeted) therapy strategy to ALK+ ALCL, a non-Hodgkin peripheral T-cell lymphoma that depends on the activity of ALK fusion proteins, which support cancer growth by constant activation of JAK/STAT, RAS/MEK/ERK and PI3K/AKT pathways [2,3]. This evidence concerns the gene ALK and anaplastic large cell lymphoma.